Cytokine Production and Immune Cell Activation in Melanoma Patients Treated with Liposomal Muramyl Tripeptide (CGP 19835A Lipid)1
| Autor: | Wakae Fujimaki, Kyogo Itoh, Jacalyn B. Gano, Taeha An, Lazel B. Augustus, Isaiah J. Fidler, Dennis A. Johnston, Dmitri D. Karkevitch, Eugenie S. Kleinerman, Paul F. Mansfield, Charles M. Balch, Merrick I. Ross |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Pharmacology
Cancer Research medicine.medical_specialty Tumor-infiltrating lymphocytes medicine.drug_class business.industry medicine.medical_treatment Melanoma Neopterin Immunotherapy medicine.disease Gastroenterology Immunostimulant Surgery chemistry.chemical_compound Immune system Cytokine chemistry Internal medicine medicine business Progressive disease |
| Zdroj: | Cancer Biotherapy. 8:307-318 |
| ISSN: | 1062-8401 |
| DOI: | 10.1089/cbr.1993.8.307 |
| Popis: | We conducted a pilot study using liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) preoperatively in patients with stage III or IV resectable melanoma who were at high risk for recurrence. Patients received L-MTP-PE for 1 month before surgery and then 5 months postoperatively. Several immune parameters were monitored during preoperative therapy to search for correlations with clinical (tumor) response. The 18 patients were classified into three groups according to their responses and disease-free intervals: no evidence of disease (NED) at week 24 of therapy, relapse during therapy and progressive disease on therapy noted at the time of surgery. Six of nine patients in the NED group demonstrated increased monocyte tumoricidal activity (MTA) during week 1 of therapy. MTA increased in three of the six patients in the relapse group. MTA did not increase in the three patients who had progressive disease on therapy. Plasma neopterin levels were elevated by 72 h following the first L-M... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|